Yen-Huang Chen, MD
Urology · Kirkland, WANPI 1841335171
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in WA, where the typical reported total is $1,712.
Across 39 payments — averaging $52.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$326
- Procept Biorobotics Corporation$293
- Myriad Genetic Laboratories, Inc.$247
- Olympus America Inc.$232
- Davol Inc.$172
- C. R. Bard, Inc. & Subsidiaries$162
- plus $632 from 12 others
What the payments were for
- Food & beverage$2,060100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $326 |
| Procept Biorobotics Corporation | 3 | $293 |
| Myriad Genetic Laboratories, Inc. | 2 | $247 |
| Olympus America Inc. | 3 | $232 |
| Davol Inc. | 1 | $172 |
| C. R. Bard, Inc. & Subsidiaries | 7 | $162 |
| Sumitomo Pharma America, Inc. | 1 | $96 |
| AbbVie | 1 | $85 |
| Progenics Pharmaceuticals, Inc. | 3 | $83 |
| Pfizer | 1 | $83 |
| 180 Medical, Inc. | 3 | $78 |
| Astellas Pharma US Inc | 1 | $69 |
| Urogen Pharma, Inc. | 2 | $60 |
| Coloplast | 1 | $20 |
| Immunitybio, Inc. | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $17 |
| ABC Home Medical Supply, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,064 in reported general payments places this provider in the 50th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 39 | $20,318 |
| MyrbetriqMirabegron | 14 | $10,038 |
| Tamsulosin Hcl | 307 | $5,627 |
| Finasteride | 360 | $4,769 |
| Methenamine Hippurate | 13 | $1,250 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $1,228 |
| Dutasteride | 22 | $414 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 26 | $341 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 43 | $285 |
| Bicalutamide | 16 | $282 |
| Prochlorperazine Maleate | 43 | $261 |
| Cephalexin | 15 | $201 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 58 | $181 |
| Ciprofloxacin Hcl | 23 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $96 | $20,31839 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $10,03814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 274 urology providers in Washington.
Other urology in Kirkland
- Kevin OstrowskiKirkland$64K
- Sabrina StairKirkland$9K
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Raymond LanceSpokane$211K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Marco SalazarEdmonds$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.